866-997-4948(US-Canada Toll Free)

Levemir (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 46 Pages


GlobalData has released its new report, Levemir (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Levemir (insulin detemir) is a long-acting human insulin analog developed by Novo Nordisk and launched in 2005. It contains a fatty acid (myristic acid) bound to the amino acid Lysine at position B29. This fatty acid helps its binding to albumin in blood, forming a depot product that gradually releases insulin into the tissues.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Levemir including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Levemir for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Levemir performance
  • Obtain sales forecast for Levemir from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Levemir (insulin detemir) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 29
6.4 SWOT Analysis 30
6.5 Forecast 31

7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 35
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosed Type 2 Patients 37
7.4.2 Percent Drug-Treated Patients 38
7.4.3 Drugs Included in Each Therapeutic Class 38
7.4.4 Launch and Patent Expiry Dates 39
7.4.5 General Pricing Assumptions 39
7.4.6 Individual Drug Assumptions 40
7.4.7 Generic Erosion 40
7.5 Physicians and Specialists Included in this Study 41
7.6 About the Authors 43
7.6.1 Analyst II - CVMD 43
7.6.2 Therapy Director - CVMD and Infectious Disease 43
7.6.3 Global Head of Healthcare 44
7.7 About GlobalData 45
7.8 Disclaimer 45

List of Table


Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Product Profile - Levemir 28
Table 7: Levemir SWOT Analysis, 2012 30
Table 8: Global Sales Forecasts ($m) for Levemir, 2012-2022 31
Table 9: Key Launch Dates 39
Table 10: Key Patent Expiries 39
Table 11: Number of High-Prescribing Physicians Surveyed 42

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *